WillItSurvive
Pharma and healthcare groups · Japan

Takeda Pharmaceutical Company

takeda.com ↗

Japanese pharma giant selling patent-protected drugs and plasma-derived therapies worldwide.

Hard to displace
Assessed 24 July 2026 · Evidence as of 24 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 24 July 2026 · Checkable from Q1 2027 · Every call on the record Checkpoint: FDA decision on Alvotech's AVT16 Entyvio biosimilar
The call

Takeda's revenue rests on patent-protected drugs and plasma supply chains that a biosimilar filing and an antitrust verdict are now testing.

Takeda makes prescription medicines and collects blood plasma for treatments, selling to hospitals and patients in over 80 countries. It is hard to replace because the company has drugs approved by the FDA with patent protections lasting years, owns expensive plasma-collection facilities that few competitors can match, and has built relationships with doctors worldwide over decades. The biggest risk is that cheaper copycat versions of its top drug, Entyvio, could arrive around early 2027, and a legal case over another drug called AMITIZA could cost money, but even if both happen, the company has enough variety and cash to stay standing for several more years.

Why
01
AI pressure: AI drug-discovery labs like Insilico Medicine and Isomorphic Labs. AI-native biotechs could speed up rival drug discovery, but Takeda uses AI as a partner, not a competitor, so far. Could AI do the core job? Unlikely.
02
Bigger players: Alvotech (AVT16, an Entyvio biosimilar). Alvotech's copy of Takeda's top-selling drug Entyvio is under FDA review, with a decision expected around Q1 2027. Could a giant copy it? No, they are blocked.
03
What protects it. Entyvio patent protection until 2032, plus plasma-collection infrastructure that takes years and capital to replicate.
What would change this call
FDA decision on Alvotech's AVT16 Entyvio biosimilar around Q1 2027. Approval would open Entyvio to price competition and erode Takeda's top product revenue.
Appeals court ruling on the $885M AMITIZA antitrust verdict. Upholding or trebling damages to over $2B would strain cash flow and pipeline funding.
FDA approval outcomes for oveporexton, rusfertide, and zasocitinib through 2026-2027. Multiple failures would signal weakening pipeline replacement for aging blockbusters.
Key numbers
  • AMITIZA verdict: $885M, could exceed $2B if trebled (2026-05-18)
  • Entyvio patent protection runs until 2032 (2026-06-08)
  • Julie Kim became CEO on June 24, 2026 (2026-06-24)
Named risks
  • AMITIZA antitrust damages could reach over $2B after trebling, pending appeal. Severity: high
  • Entyvio biosimilar (Alvotech AVT16) could erode flagship GI franchise starting Q1 2027. Severity: high
  • New CEO transition (June 2026) coincides with three major near-term product launches. Severity: medium
  • Three pipeline launches (oveporexton, rusfertide, zasocitinib) could underperform or fail to reach approval. Severity: medium
  • Overall revenue already declined 1.66% YoY in FY2025, indicating flat-to-negative growth trajectory. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
CSL BehringcontestingLargest plasma-derived therapies market share rival to Takeda's PDT segment, as of March 2026 analysis
GrifolscontestingMajor competitor in plasma-derived therapeutics, ongoing as of 2026
AbbViecontestingSkyrizi and Humira compete with Entyvio in inflammatory bowel disease as of 2026
Rochelosing toHemlibra has materially disrupted Takeda's Shire-derived hemophilia franchise, per 2026 market reports
Alvotechgaining onAVT16 Entyvio biosimilar under FDA review, decision possible Q1 2027
SanoficontestingSanofi's Wayrilz approved August 2025 as new rare hematology entrant competing in Takeda's rare disease space
Questions people ask
Is Takeda Pharmaceutical profitable in 2026?
Yes, Takeda reported FY2025 (ended March 31, 2026) revenue of about JPY 4,505.7 billion (roughly $30B) with basic EPS of JPY 121.75, though revenue was down 1.66% year over year amid cost discipline and legal charges from the AMITIZA verdict.
Is Takeda facing layoffs in 2026?
Headcount is broadly flat to modestly declining, not a mass layoff event. Company-linked data show 47,029 employees as of March 31, 2026, down 426 (-0.90%) year over year, consistent with ongoing post-Shire cost discipline rather than active cuts.
Could AI replace Takeda's drug discovery work?
AI can accelerate early discovery, Takeda's July 1, 2026 deal with Insilico Medicine (up to $600M) uses AI for target ID and molecule design, but it cannot replace FDA approval, manufacturing, patent estates like Entyvio (protected to 2032), or liability accountability, which remain human/corporate functions.
Who is Takeda Pharmaceutical's biggest competitor?
In plasma-derived therapies, CSL Behring and Grifols are Takeda's closest rivals. In gastroenterology, AbbVie's Skyrizi and Humira franchise compete with Entyvio, while Roche's Hemlibra has disrupted Takeda's Shire-derived hemophilia business, per multiple third-party market reports as of mid-2026.
Who owns Takeda Pharmaceutical?
Takeda is a publicly traded company with no controlling parent, listed on the Tokyo Stock Exchange (4502) and NYSE (TAK). Its most significant ownership-shaping event was the $62 billion acquisition of Shire plc, completed January 8, 2019, which nearly doubled its revenue base.
Will Takeda's Entyvio face biosimilar competition soon?
Yes. Alvotech's AVT16, a biosimilar to Entyvio, is under FDA review with a possible decision around Q1 2027, per a June 8, 2026 report. Entyvio itself has US patent protection until 2032, but biosimilar entry could still pressure sales beginning in 2027.
Timeline
  • 2026-07-01Takeda signs up to $600M AI drug discovery deal with Insilico Medicine
  • 2026-06-24Julie Kim becomes President and CEO, succeeding Christophe Weber
  • 2026-06-09FDA accepts sBLA for pediatric IV Entyvio, PDUFA date Q1 2027
  • 2026-06-08FDA begins review of Alvotech's AVT16 Entyvio biosimilar, decision possible Q1 2027
  • 2026-05-19Takeda announces it will appeal AMITIZA antitrust jury verdict
  • 2026-05-18Jury awards ~$885M in AMITIZA pay-for-delay antitrust case against Takeda
  • 2026-05-13Takeda reports FY2025 full year results and FY2026 outlook
  • 2026-01-08Takeda and Halozyme announce ENHANZE licensing deal for subcutaneous vedolizumab
  • 2025-01-30Takeda announces Julie Kim will succeed Christophe Weber as CEO in June 2026
  • 2019-01-08Takeda completes $62 billion acquisition of Shire plc
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources